Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Inflammatory Bowel Diseases

  Free Subscription


01.01.2020

7 Aliment Pharmacol Ther
5 Am J Gastroenterol
1 BMC Gastroenterol
3 Clin Gastroenterol Hepatol
6 Dig Dis Sci
4 Eur J Gastroenterol Hepatol
2 Gastroenterol Hepatol
13 Gastroenterology
7 Gut
19 Inflamm Bowel Dis
6 J Crohns Colitis
1 J Gastroenterol
5 N Engl J Med
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. YAMAMOTO T, Shimoyama T, Kotze PG
    Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:189-190.
    PubMed     Text format    

  2. OLLECH JE, Dwadasi S, Rai V, Peleg N, et al
    Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Dec 25. doi: 10.1111/apt.15616.
    PubMed     Text format     Abstract available

  3. KAYAL M, Ungaro R
    Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:190.
    PubMed     Text format    

  4. LAHARIE D, Riviere P
    Letter: should we intensify infliximab in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:186-187.
    PubMed     Text format    

  5. SEBASTIAN S
    Letter: should we intensify infliximab in acute severe ulcerative colitis? Author's reply.
    Aliment Pharmacol Ther. 2020;51:188.
    PubMed     Text format    

  6. HYAMS JS, Dubinsky M, Rosh J, Ruemmele FM, et al
    The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
    Aliment Pharmacol Ther. 2019;49:155-164.
    PubMed     Text format     Abstract available

  7. HALMOS EP, Mack A, Gibson PR
    Review article: emulsifiers in the food supply and implications for gastrointestinal disease.
    Aliment Pharmacol Ther. 2019;49:41-50.
    PubMed     Text format     Abstract available


    Am J Gastroenterol

  8. BERENBLUM C
    An Issue of Control: Patient Perspectives on Use of Nutritional Interventions for IBD.
    Am J Gastroenterol. 2019;114:192-193.
    PubMed     Text format    

  9. GUPTA N, Hanauer SB
    Too Soon to Discard 5-ASAs?
    Am J Gastroenterol. 2019;114:534-535.
    PubMed     Text format    

  10. HE Y, Zhu Z, Chen Y, Chen F, et al
    Development and Validation of a Novel Diagnostic Nomogram to Differentiate Between Intestinal Tuberculosis and Crohn's Disease: A 6-year Prospective Multicenter Study.
    Am J Gastroenterol. 2019;114:490-499.
    PubMed     Text format     Abstract available

  11. SINGH S, Jairath V
    Response to Gupta and Hanauer.
    Am J Gastroenterol. 2019;114:535-536.
    PubMed     Text format    

  12. FRIEDMAN S, Norgard BM
    Response to Zhao et al.
    Am J Gastroenterol. 2019;114:358-359.
    PubMed     Text format    


    BMC Gastroenterol

  13. SNOWDEN JA, Hawkey C, Hind D, Swaby L, et al
    Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study.
    BMC Gastroenterol. 2019;19:82.
    PubMed     Text format     Abstract available


    Clin Gastroenterol Hepatol

  14. HIRTEN RP, Lakatos PL, Halfvarson J, Colombel JF, et al
    A Users Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31499.
    PubMed     Text format     Abstract available

  15. PAI RK, Hartman DJ, Rivers CR, Regueiro M, et al
    Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Dec 13. pii: S1542-3565(19)31438.
    PubMed     Text format     Abstract available

  16. SIEGEL CA, Thompson KD, Walls D, Gollins J, et al
    Crohn's disease patients' and gastroenterologists' perspectives towards de-escalating inflammatory bowel disease therapy.
    Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31498.
    PubMed     Text format    


    Dig Dis Sci

  17. CLARK-SNUSTAD KD, Singla A, Lee SD
    Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Dig Dis Sci. 2019;64:1952-1958.
    PubMed     Text format     Abstract available

  18. MENG Y, Li Y, Hao R, Li X, et al
    Analysis of Phenotypic Variables and Differentiation Between Untypical Crohn's Disease and Untypical Intestinal Tuberculosis.
    Dig Dis Sci. 2019 Feb 6. pii: 10.1007/s10620-019-05491.
    PubMed     Text format     Abstract available

  19. SCHAD CA, Haac BE, Cross RK, Syed A, et al
    Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn's Disease.
    Dig Dis Sci. 2019;64:1959-1966.
    PubMed     Text format     Abstract available

  20. WASZCZUK L, Waszczuk K, Waszczuk E
    CT in Crohn's Disease Is Beneficial for Patient Care and Should Not Be Feared.
    Dig Dis Sci. 2019;64:2056-2058.
    PubMed     Text format    

  21. TORRES P, Canete F, Nunez L, Aguilar A, et al
    Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
    Dig Dis Sci. 2019 Dec 19. pii: 10.1007/s10620-019-06010.
    PubMed     Text format     Abstract available

  22. WEISSHOF R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, et al
    Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
    Dig Dis Sci. 2019;64:1945-1951.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  23. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Murrells T, et al
    Developing a better biopsychosocial understanding of pain in inflammatory bowel disease: a cross-sectional study.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001615.
    PubMed     Text format     Abstract available

  24. ALGETHMI W, Baumann C, Alnajjar W, Sroji A, et al
    Environmental exposures and the risk of inflammatory bowel disease: a case-control study from Saudi Arabia.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001619.
    PubMed     Text format     Abstract available

  25. KUMAR A, Lukin DJ
    Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001648.
    PubMed     Text format     Abstract available

  26. NERI B, Stingone C, Romeo S, Sena G, et al
    Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001605.
    PubMed     Text format     Abstract available


    Gastroenterol Hepatol

  27. BOSCA MM, Alos R, Maroto N, Gisbert JP, et al
    Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease.
    Gastroenterol Hepatol. 2019 Dec 20. pii: S0210-5705(19)30259.
    PubMed     Text format     Abstract available

  28. FRASER CG
    Faecal immunochemical tests for haemoglobin (FIT) in the assessment of patients with lower abdominal symptoms: current controversies.
    Gastroenterol Hepatol. 2019;42:263-270.
    PubMed     Text format     Abstract available


    Gastroenterology

  29. BAR-YOSEPH H, Pressman S, Blatt A, Gerassy Vainberg S, et al
    Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
    Gastroenterology. 2019;157:1338-1351.
    PubMed     Text format     Abstract available

  30. GUNTHER C, Ruder B, Stolzer I, Dorner H, et al
    Interferon Lambda Promotes Paneth Cell Death Via STAT1 Signaling in Mice and Is Increased in Inflamed Ileal Tissues of Patients With Crohn's Disease.
    Gastroenterology. 2019;157:1310-1322.
    PubMed     Text format     Abstract available

  31. HINDRYCKX P, Jairath V, Zou G, Feagan BG, et al
    Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease.
    Gastroenterology. 2019;157:1233-1244.
    PubMed     Text format     Abstract available

  32. ADEN K, Rehman A, Waschina S, Pan WH, et al
    Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Gastroenterology. 2019;157:1279-1292.
    PubMed     Text format     Abstract available

  33. KUO WT, Shen L, Zuo L, Shashikanth N, et al
    Inflammation-induced Occludin Downregulation Limits Epithelial Apoptosis by Suppressing Caspase-3 Expression.
    Gastroenterology. 2019;157:1323-1337.
    PubMed     Text format     Abstract available

  34. ZHU Y, Johnson LA, Rubin JM, Appelman H, et al
    Strain-Photoacoustic Imaging as a Potential Tool for Characterizing Intestinal Fibrosis.
    Gastroenterology. 2019;157:1196-1198.
    PubMed     Text format    

  35. DANESE S
    New Drugs In The Ulcerative Colitis Pipeline: Prometheus Unbound.
    Gastroenterology. 2019 Dec 17. pii: S0016-5085(19)41924.
    PubMed     Text format    

  36. GRIMAUD F, Serrero M, Magalon J
    Adipose-Derived Therapeutic Products for the Management of Refractory Crohn's Fistula.
    Gastroenterology. 2019;157:1690-1691.
    PubMed     Text format    

  37. GUO Y, Bai AP
    Plasticity of Th17 Cells Contributes to Crohn's Disease.
    Gastroenterology. 2019;157:1689.
    PubMed     Text format    

  38. ALAMEEL T, Al Sulais E
    Ustekinumab and Pregnancy: Continue or Cease Before You Conceive?
    Gastroenterology. 2019;157:1435.
    PubMed     Text format    

  39. BERNSTEIN CN
    Reply.
    Gastroenterology. 2019;157:1443-1444.
    PubMed     Text format    

  40. MAHADEVAN U, Fisher S, Riley L, Chambers C, et al
    Reply.
    Gastroenterology. 2019;157:1435-1436.
    PubMed     Text format    

  41. SHAH SC
    Friend or Foe in Inflammatory Bowel Disease Pathogenesis: Not All Infections Are Equal.
    Gastroenterology. 2019;157:1441-1442.
    PubMed     Text format    


    Gut

  42. TULKENS J, Vergauwen G, Van Deun J, Geeurickx E, et al
    Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.
    Gut. 2020;69:191-193.
    PubMed     Text format    

  43. WAN QY, Zhao R, Wu XT
    Older patients with IBD might have higher risk of Parkinson's disease.
    Gut. 2020;69:193-194.
    PubMed     Text format    

  44. TURNER D, Griffiths AM, Wilson D, Mould DR, et al
    Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary.
    Gut. 2020;69:32-41.
    PubMed     Text format     Abstract available

  45. TORRES J, Hu J, Seki A, Eisele C, et al
    Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice.
    Gut. 2020;69:42-51.
    PubMed     Text format     Abstract available

  46. NG SC, Kamm MA, Yeoh YK, Chan PKS, et al
    Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE).
    Gut. 2020;69:83-91.
    PubMed     Text format     Abstract available

  47. MAASER C, Petersen F, Helwig U, Fischer I, et al
    Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study.
    Gut. 2019 Dec 20. pii: gutjnl-2019-319451. doi: 10.1136/gutjnl-2019-319451.
    PubMed     Text format     Abstract available

  48. LEMOINNE S, Kemgang A, Ben Belkacem K, Straube M, et al
    Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.
    Gut. 2019 Apr 19. pii: gutjnl-2018-317791. doi: 10.1136/gutjnl-2018-317791.
    PubMed     Text format     Abstract available


    Inflamm Bowel Dis

  49. STEINHART AH, Panaccione R, Targownik L, Bressler B, et al
    Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.
    Inflamm Bowel Dis. 2019;25:1-13.
    PubMed     Text format     Abstract available

  50. CUSHING KC, Mclean R, McDonald KG, Gustafsson JK, et al
    Predicting Risk of Postoperative Disease Recurrence in Crohn's Disease: Patients With Indolent Crohn's Disease Have Distinct Whole Transcriptome Profiles at the Time of First Surgery.
    Inflamm Bowel Dis. 2019;25:180-193.
    PubMed     Text format     Abstract available

  51. SPENCER E, Norris E, Williams C, Dubinsky MC, et al
    The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
    Inflamm Bowel Dis. 2019;25:142-149.
    PubMed     Text format     Abstract available

  52. EL-MATARY W, Walters TD, Huynh HQ, deBruyn J, et al
    Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children.
    Inflamm Bowel Dis. 2019;25:150-155.
    PubMed     Text format     Abstract available

  53. SAROLI PALUMBO C, Restellini S, Chao CY, Aruljothy A, et al
    Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
    Inflamm Bowel Dis. 2019;25:124-133.
    PubMed     Text format     Abstract available

  54. DOTSON JL, Kappelman MD, Bricker J, Andridge R, et al
    Multicenter Evaluation of Emergency Department Treatment for Children and Adolescents With Crohn's Disease According to Race/Ethnicity and Insurance Payor Status.
    Inflamm Bowel Dis. 2019;25:194-203.
    PubMed     Text format     Abstract available

  55. LEGA S, Phan BL, Rosenthal CJ, Gordon J, et al
    Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
    Inflamm Bowel Dis. 2019;25:134-141.
    PubMed     Text format     Abstract available

  56. DELDAY M, Mulder I, Logan ET, Grant G, et al
    Bacteroides thetaiotaomicron Ameliorates Colon Inflammation in Preclinical Models of Crohn's Disease.
    Inflamm Bowel Dis. 2019;25:85-96.
    PubMed     Text format     Abstract available

  57. ZHANG YG, Lu R, Xia Y, Zhou D, et al
    Lack of Vitamin D Receptor Leads to Hyperfunction of Claudin-2 in Intestinal Inflammatory Responses.
    Inflamm Bowel Dis. 2019;25:97-110.
    PubMed     Text format     Abstract available

  58. ESCUDERO-HERNANDEZ C, Montalvillo E, Antolin B, Bernardo D, et al
    Different Intraepithelial CD3+ Cell Numbers in Crohn's Disease and Ulcerative Colitis.
    Inflamm Bowel Dis. 2019 Dec 28. pii: 5688873. doi: 10.1093.
    PubMed     Text format    

  59. KEVANS D, Kirsch R, Dargavel C, Kabakchiev B, et al
    Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis.
    Inflamm Bowel Dis. 2019 Dec 28. pii: 5688912. doi: 10.1093.
    PubMed     Text format     Abstract available

  60. DAI C, Jiang M, Sun MJ
    Disease Duration and the Risk of Treatment Failure in Biologic-Treated Patients with Ulcerative Colitis.
    Inflamm Bowel Dis. 2019 Dec 30. pii: 5690100. doi: 10.1093.
    PubMed     Text format    

  61. FAYE AS, Oh A, Kumble LD, Kiran RP, et al
    Fertility Impact of Initial Operation Type for Female Ulcerative Colitis Patients.
    Inflamm Bowel Dis. 2019 Dec 27. pii: 5688242. doi: 10.1093.
    PubMed     Text format     Abstract available

  62. LUTHER J, Dave M
    Rising Inflammatory Bowel Disease Prevalence Highlights the Need for Effective, Cost-Effective Therapies.
    Inflamm Bowel Dis. 2019 Sep 7. pii: 5565004. doi: 10.1093.
    PubMed     Text format    

  63. KANE S
    Contraception and Antibiotics.
    Inflamm Bowel Dis. 2019;25:e148.
    PubMed     Text format    

  64. MIRJALALI H, Shahrokh S, Asadzadeh Aghdaei H, Zali MR, et al
    Letter to the Editor: Activated Toxoplasma May Attenuate the Effect of Azathioprine and Deteriorate the Symptoms in IBD Patients via mTORC1 Manipulation.
    Inflamm Bowel Dis. 2019;25:e137.
    PubMed     Text format    

  65. BUTTO LF, Jia LG, Arseneau KO, Tamagawa H, et al
    Death-Domain-Receptor 3 Deletion Normalizes Inflammatory Gene Expression and Prevents Ileitis in Experimental Crohn's Disease.
    Inflamm Bowel Dis. 2019;25:14-26.
    PubMed     Text format     Abstract available

  66. DEBRUYN J
    Response to the Letter by Dr. Freddy Calder.
    Inflamm Bowel Dis. 2019;25:e104.
    PubMed     Text format    

  67. RENOUF MJ, Cho YH, McPhee JB
    Emergent Behavior of IBD-Associated Escherichia coli During Disease.
    Inflamm Bowel Dis. 2019;25:33-44.
    PubMed     Text format     Abstract available


    J Crohns Colitis

  68. KOBAYASHI T, Uda A, Udagawa E, Hibi T, et al
    Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
    J Crohns Colitis. 2019 Dec 23. pii: 5684917. doi: 10.1093.
    PubMed     Text format     Abstract available

  69. FLEMING C, Mohan H, Coffey JC
    Should we Resect the Mesentery in Ileocolic Crohn's Disease?-A Response to 'A Warning About the Role of Extended Mesenteric Resection in Crohn's Disease Recurrence'.
    J Crohns Colitis. 2019;13:1584.
    PubMed     Text format    

  70. PANACCIONE R, Lofberg R, Rutgeerts P, Sandborn WJ, et al
    Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
    J Crohns Colitis. 2019;13:725-734.
    PubMed     Text format     Abstract available

  71. BURR NE, Hall B, Hamlin PJ, Selinger CP, et al
    Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease.
    J Crohns Colitis. 2019;13:693-701.
    PubMed     Text format     Abstract available

  72. BARNHOORN MC, Van Halteren AGS, Van Pel M, Molendijk I, et al
    Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report.
    J Crohns Colitis. 2019;13:807-811.
    PubMed     Text format     Abstract available

  73. FERRANTE M, Sabino J
    Efficacy of anti-JAK inhibitors in ulcerative colitis.
    J Crohns Colitis. 2019 Dec 27. pii: 5687770. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Gastroenterol

  74. YASUKAWA S, Matsui T, Yano Y, Sato Y, et al
    Crohn's disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan.
    J Gastroenterol. 2019;54:42-52.
    PubMed     Text format     Abstract available


    N Engl J Med

  75. ROWAN CR, Boland K, Harewood GC
    Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    N Engl J Med. 2020;382:91.
    PubMed     Text format    

  76. SANDS BE, Marano C
    Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply.
    N Engl J Med. 2020;382:91.
    PubMed     Text format    

  77. BIEMANS VBC, Hoentjen F, Pierik MJ
    Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    N Engl J Med. 2020;382:92.
    PubMed     Text format    

  78. O'CONNOR DB, Lahiff C
    Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    N Engl J Med. 2020;382:92-93.
    PubMed     Text format    

  79. SANDS BE, Schreiber S, Lirio RA
    Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply.
    N Engl J Med. 2020;382:93-94.
    PubMed     Text format    


    PLoS One

  80. LI E, Zhang Y, Tian X, Wang X, et al
    Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome.
    PLoS One. 2019;14:e0213108.
    PubMed     Text format     Abstract available

  81. HAISMA SM, Galaurchi A, Almahwzi S, Adekanmi Balogun JA, et al
    Head-to-head comparison of three stool calprotectin tests for home use.
    PLoS One. 2019;14:e0214751.
    PubMed     Text format     Abstract available

  82. ATHERLY T, Rossi G, White R, Seo YJ, et al
    Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease.
    PLoS One. 2019;14:e0226780.
    PubMed     Text format     Abstract available

  83. COLONETTI K, Bento Dos Santos B, Nalin T, Moura de Souza CF, et al
    Hepatic glycogen storage diseases are associated to microbial dysbiosis.
    PLoS One. 2019;14:e0214582.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: